ArticleJACC. Case reports2025
Transcatheter Tricuspid Valve Replacement in Torrential Tricuspid Regurgitation With Severe Right Ventricular Dysfunction.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTorrential tricuspid regurgitation (TR) with right heart failure poses management challenges, particularly in patients ineligible for surgery or transcatheter edge-to-edge repair. CASE SUMMARY: A 61-year-old man with torrential TR, severe right ventricular (RV) dilation (6.2 cm), and severe RV dysfunction presented with NYHA functional class IV symptoms. He was refractory to diuretics and inotropes and was declined for surgery, transcatheter edge-to-edge repair, and transplant. He underwent transcatheter tricuspid valve replacement with the LuX-Valve Plus. Postprocedure echocardiography showed improved RV end-diastolic area, RV fractional area change, and RV strain, with RV function improving to mild-moderate. He improved symptomatically but later died from unrelated complications. DISCUSSION: This case illustrates the feasibility of the LuX-Valve Plus in torrential TR with severe RV dysfunction and dilation. Procedural success and early signs of RV remodeling were achieved. TAKE-HOME MESSAGES: Transcatheter tricuspid valve replacement with the LuX-Valve Plus is viable in high-risk TR patients. Multiparametric RV assessment is essential for guiding intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.